Mohamed Kazamel, MD
Neurology · Scottsdale, AZNPI 1013144484
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,680 of the $15,048 with a category attached, or 77.6%. Alnylam Pharmaceuticals Inc. accounts for 69.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $8,278 and has fallen 95.3% since, to $390 in 2024.
Across 42 payments — averaging $358.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$10K
- Akcea Therapeutics, Inc.$4K
- Boston Scientific$254
- UCB, Inc.$134
- AstraZeneca$132
- CSL Behring$124
- plus $115 from 1 others
Across 8 payments — averaging $8152.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$47K
- AstraZeneca$18K
What the payments were for
- Consulting fees$11,68078%
- Speaking & faculty fees$1,92513%
- Travel & lodging$2262%
- Food & beverage$1,2178%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 9 | $10,407 |
| Akcea Therapeutics, Inc. | 6 | $3,882 |
| Boston Scientific | 23 | $254 |
| UCB, Inc. | 1 | $134 |
| AstraZeneca | 1 | $132 |
| CSL Behring | 1 | $124 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,048 in reported general payments places this provider in the 75th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 25 | $1,196,587 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 65 | $1,029,398 |
| Radicava OrsEdaravone | 66 | $948,795 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 69 | $858,657 |
| OnpattroPatisiran Sodium,lipid Complex | 17 | $491,084 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 14 | $322,780 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 19 | $295,852 |
| RadicavaEdaravone | 13 | $129,089 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $106,510 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 23 | $12,195 |
| Riluzole | 88 | $10,081 |
| Pregabalin | 130 | $6,980 |
| Pyridostigmine Bromide | 119 | $6,386 |
| Azathioprine | 41 | $4,043 |
| Baclofen | 59 | $3,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $124 | $858,65769 claims |
| Alnylam Pharmaceuticals Inc.Onpattro | $10,407 | $491,08417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 neurology providers in Arizona.
Other neurology in Scottsdale
- Nida LaurinScottsdale$969K
- Dean WingerchukScottsdale$324K
- Amaal StarlingScottsdale$315K
- Virgilio Gerald EvidenteScottsdale$231K
- Brent GoodmanScottsdale$198K
- David SapersteinScottsdale$135K
- Maciej MrugalaScottsdale$97K
- Charles AdlerScottsdale$74K
- Jill RauScottsdale$59K
- Shyamal MehtaScottsdale$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.